Pictogram of Biomatrix biodegradable polymerProven Safety of a DES
with an Abluminal Biodegradable Polymer

 

Confirmed Safety
  • with a 12.3% reduction in MACE compared to the Sirolimus eluting stent at 12 months in LEADERS2
  • with no late or very late stent thrombosis in STEALTH I3 out to 4 years

Superior strut coverage at follow up 

10 times better strut coverage4 of an abluminal biodegradable polymer BES than a durable symmetric polymer SES

  • Abluminal biodegradable polymer BES achieves 96.4% of near to complete strut coverage

Superior stent apposition 

More than 20 times better stent apposition4 of an abluminal biodegradable polymer BES than a durable symmetric polymer SES


Biolimus A9™ eluting stent with abluminal biodegradable polymer demonstrates preserved vasomotion
  • A high pacing stimulation induced abnormal vasomotion5 (vasoconstruction) of the Sirolimus eluting stented vessel when normal vasomotion (vasodilation) was observed in the Biolimus A9™ eluting stented vessel


* Data on file - molecular weight <10kDa
2. Serruys P.W., LEADERS: Taking the LEAD in DES Clinical Excellence - 12 months results, oral presentation, TCT 2008. Data applicable to the stent used in the LEADERS trial
3. Grube E., Safety and Performance Evaluation of Biosensors Biolimus A9™ Eluting Stent (BioMatrix™) STEALTH I: a 4-year safety follow-up, e-poster, TCT 2008
4. Di Mario C., OCT: Differences between biodegradable and durable polymers - Insights from the LEADERS trial, oral presentation, TCT 2008. Data applicable to the stent used in the LEADERS trial
5. Hamilos M. et al. on behalf of the Nobori Core investigators, Differential Effects of Drug-Eluting Stents on Local Endothelium-Dependent Coronary Vasomotion, J Am Coll Cardiol 2008 51:2123-2129. Data applicable to the stent used in the Nobori Core trial

CAUTION: The law restricts these devices to sale by or on the order of a physician. Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.

Biosensors’ interventional cardiology products, including BioMatrix Flex™, BioMatrix NeoFlex™, BioMatrix™, Axxess™, BioFreedom™, Chroma™, BioStream™, BioPath™, Gazelle™, Juno™, S-Stent™, Powerline™, Quadrature Link™ and MultiPleat™, are not available for sale in the United States and certain other countries. All other trademarks are the property of their respective owners.

BioMatrix Flex, BioMatrix NeoFlex, BioMatrix, Axxess, BioFreedom, Chroma, BioStream, BioPath, Gazelle, Juno, S-Stent, Powerline, Quadrature Link and MultiPleat are trademarks or registered trademarks of Biosensors International Group, Ltd. in the United States and certain other countries. All cited trademarks are the property of their respective owners.